摘要
目的探讨替吉奥联合奥沙利铂方案（SOX方案）和紫杉醇联合奥沙利铂和5-氟尿嘧啶方案（POF方案）治疗晚期胃癌的疗效和不良反应。方法收集2010年2月至2013年6月间晚期胃癌患者48例,分为SOX组和POF组,分别采用SOX方案（23例）和POF方案（25例）。至少完成2个周期化疗,比较两组患者的疗效和不良反应。结果 SOX组患者的有效率（RR）为47.8%,疾病控制率（DCR）为65.2%;POF组患者的RR为44.0%,DCR为68.0%,两组差异均无统计学意义（均P〉0.05）。SOX组患者的中位疾病进展时间（TTP）为7.2个月,中位总生存期（OS）为11.5个月;POF组患者的TTP为8.4个月,OS为12.3个月,两组差异均无统计学意义（均P〉0.05）。两组患者的不良反应也相似,以Ⅰ-Ⅱ级的血液学毒性和消化道反应为主。SOX组患者的血小板减少发生率高于POF组（P〈0.05）,POF组患者脱发发生率高于SOX组（P〈0.05）。结论 SOX方案治疗晚期胃癌疗效与POF方案相似,耐受性好,应用更方便。
Objective To evaluate the efficacy and toxicity of S-1 combined with oxaliplatine （SOX） and paclitaxel and oxaliplat combined with 5-fluorouracil （POF） in the treatment of patients with advanced gastric cancer. Methods Fourty-eight patients with advanced gastric cancer were enrolled into this study. They were divided into SOX group and POF group respectively. All patients received two cycles of chemotherapy at least. The efficacy and toxicity were evaluated. Results The treatment response rate （RR） in the SOX group and POF group was similar （47. 8% vs 44.0%, x^2 =0. 071, P 〉0. 05）. The time to progression （TIP） in the SOX group and POF group was 7.2 mo and 8.4 mo respectively （P 〉0. 05）. The overall survival （OS） in the SOX group and POF group was 11.5 mo and 12. 3 mo respectively （ P 〉 0.05）. Thrombocytopenia in the SOX group were significantly higher than that in the POF group （ P 〈 0.05） ; Alopecia in the SOX group were significantly lower than that in the POF group （ P 〈 0. 05 ）. Conclusion The response of SOX regimen for advanced gastric cancer is similar, and the toxicity of SOX is tolerable.
出处
《中国肿瘤临床与康复》
2014年第12期1489-1492,共4页
Chinese Journal of Clinical Oncology and Rehabilitation
关键词
胃肿瘤
替吉奥
药物治疗
联合
Gastric neoplasms
S1 capsule
Drug therapy, combination
